DTU
DTU

Professor Rury Holman

Picture of Rury Holman Highly Cited Researcher

Position:Emeritus Director

PA:Taryn Hastings
Diabetes Trials Unit
Tel: 01865 857240

Email:rury.holman@dtu.ox.ac.uk

ORCID ID0000-0002-1256-874X

Rury Holman trained in medicine at the University of Bristol in the United Kingdom, founded the University of Oxford Diabetes Trials Unit (DTU) in 1985, and was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998. He runs an active Translational Research Group undertaking investigator-led early phase trials of novel therapeutic agents, new medical devices and complex interventions. He also designs and runs investigator-led global cardiovascular outcome trials and is currently joint Chair of EXSCEL and TECOS, and Chief Investigator of ACE and UKPDS. In addition, has a major interest in risk prediction and has co-produced the UKPDS Risk Engine and the UKPDS Outcomes Model, which is used by NICE to assess the potential impact of antidiabetic therapies. Professor Holman has received 16 national and international awards and has published over 370 peer-reviewed papers that have been cited more than 66,000 times.

Latest publications

Manuscript
A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk
Stephen A. Williams et al.
Sci Transl Med 2022

Manuscript
Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: a cost-utility analysis based on the EXSCEL trial
Frauke Becker et al.
Diabetes Res Clin Pract. 2022;183:109152

Manuscript
Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
Abhinav Sharma et al.
Diabetes Care 2022;45:04-212

Manuscript
The effect of fenofibrate therapy on laser treatment for diabetic retinopathy: a meta-analysis of randomized controlled trials
David Preiss et al.
Diabetes Care 2022;45:e1-e2

Manuscript
Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCEL trial
Marc D. Samskya et al.
Atherosclerosis 2021;338:1-6

Manuscript
Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas
Adem Y Dawed et al.
Diabetes Care 2021;44:2673-2682